Literature DB >> 28212174

Categorizing and assessing negative symptoms.

Paola Bucci1, Silvana Galderisi.   

Abstract

PURPOSE OF REVIEW: To provide a review on studies published in the last year relevant to the categorization and assessment of negative symptoms. RECENT
FINDINGS: Recent research supported the validity of the 'deficit/non-deficit schizophrenia' categorization. Few studies confirmed the validity of the category 'persistent negative symptoms', whereas no recent study explored the validity of the category 'predominant negative symptoms'. The two-factor structure of the negative dimension is supported by studies reporting different correlates for the two subdomains: diminished expression and avolition/apathy. The need to further split avolition/apathy in two distinct components, that is anhedonia and amotivation, is confirmed in recent papers. Additional approaches to the assessment of negative symptoms have been proposed, including the self-assessment of negative symptoms, and the evaluation of negative symptoms in daily life and their assessment by means of computerized analyses.
SUMMARY: Negative symptoms represent an unmet need in the care of schizophrenia, as they are associated to poor response to available treatments and to poor functional outcome. Their accurate categorization and assessment represent a major challenge for research on neurobiological substrates and new treatment strategies.

Entities:  

Mesh:

Year:  2017        PMID: 28212174     DOI: 10.1097/YCO.0000000000000322

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  9 in total

1.  Current perspectives on incentive salience and applications to clinical disorders.

Authors:  Jeffrey J Olney; Shelley M Warlow; Erin E Naffziger; Kent C Berridge
Journal:  Curr Opin Behav Sci       Date:  2018-01-30

Review 2.  Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel.

Authors:  Andrea Fagiolini; José Ángel Alcalá; Thomas Aubel; Wojciech Bienkiewicz; Mats Magnus Knut Bogren; Joaquim Gago; Giancarlo Cerveri; Michael Colla; Francisco Collazos Sanchez; Alessandro Cuomo; Frieling Helge; Eduardo Iacoponi; Per-Axel Karlsson; Pradeep Peddu; Mauro Pettorruso; Henrique Jorge Ramos Pereira; Johan Sahlsten Schölin; Ingo Bernd Vernaleken
Journal:  Ann Gen Psychiatry       Date:  2020-09-26       Impact factor: 3.455

3.  EPA guidance on treatment of negative symptoms in schizophrenia.

Authors:  S Galderisi; S Kaiser; I Bitter; M Nordentoft; A Mucci; M Sabé; G M Giordano; M Ø Nielsen; L B Glenthøj; P Pezzella; P Falkai; S Dollfus; W Gaebel
Journal:  Eur Psychiatry       Date:  2021-03-17       Impact factor: 5.361

4.  EPA guidance on assessment of negative symptoms in schizophrenia.

Authors:  S Galderisi; A Mucci; S Dollfus; M Nordentoft; P Falkai; S Kaiser; G M Giordano; A Vandevelde; M Ø Nielsen; L B Glenthøj; M Sabé; P Pezzella; I Bitter; W Gaebel
Journal:  Eur Psychiatry       Date:  2021-02-18       Impact factor: 5.361

5.  Investigating the Relationship between White Matter Connectivity and Motivational Circuits in Subjects with Deficit Schizophrenia: A Diffusion Tensor Imaging (DTI) Study.

Authors:  Giulia M Giordano; Pasquale Pezzella; Mario Quarantelli; Paola Bucci; Anna Prinster; Andrea Soricelli; Andrea Perrottelli; Luigi Giuliani; Michele Fabrazzo; Silvana Galderisi
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241

6.  Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms.

Authors:  Koen Demyttenaere; Nicolas Leenaerts; Károly Acsai; Barbara Sebe; István Laszlovszky; Ágota Barabássy; Laura Fonticoli; Balázs Szatmári; Willie Earley; György Németh; Christoph U Correll
Journal:  Eur Psychiatry       Date:  2021-10-13       Impact factor: 5.361

7.  Negative schizophrenic symptoms as prefrontal cortex dysfunction: Examination using a task measuring goal neglect.

Authors:  Paola Fuentes-Claramonte; Núria Ramiro; Llanos Torres; Isabel Argila-Plaza; Pilar Salgado-Pineda; Joan Soler-Vidal; María Ángeles García-León; Auria Albacete; Clara Bosque; Francesco Panicalli; Ester Boix; Josep Munuera; Josep Tristany; Salvador Sarró; Miquel Bernardo; Raymond Salvador; Peter J McKenna; Edith Pomarol-Clotet
Journal:  Neuroimage Clin       Date:  2022-07-16       Impact factor: 4.891

8.  The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study.

Authors:  Elmars Rancans; Zsófia Borbála Dombi; Péter Mátrai; Ágota Barabássy; Barbara Sebe; Iveta Skrivele; György Németh
Journal:  Int Clin Psychopharmacol       Date:  2021-05-01       Impact factor: 2.023

9.  Elucidating negative symptoms in the daily life of individuals in the early stages of psychosis.

Authors:  Karlijn S F M Hermans; Inez Myin-Germeys; Charlotte Gayer-Anderson; Matthew J Kempton; Lucia Valmaggia; Philip McGuire; Robin M Murray; Philippa Garety; Til Wykes; Craig Morgan; Zuzana Kasanova; Ulrich Reininghaus
Journal:  Psychol Med       Date:  2020-05-22       Impact factor: 7.723

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.